IRVINE, Calif.--(BUSINESS WIRE)--Ivantis, Inc., developer of the novel Hydrus™ Microstent, an investigational device designed to lower eye pressure in patients with open angle glaucoma, today ...
IRVINE, CA--(Marketwired - Apr 25, 2017) - Ivantis Inc., developer of the novel Hydrus™ Microstent device, designed to lower eye pressure for glaucoma patients, announced today that the US Food and ...
GENEVA--(BUSINESS WIRE)-- Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire Ivantis®, ...
IRVINE, CA--(Marketwired - Oct 31, 2017) - Ivantis Inc., developer of the novel Hydrus™ Microstent, a device designed to lower eye pressure for open-angle glaucoma patients, announced today that it ...
The US Food and Drug Administration (FDA) has approved the Hydrus (Ivantis) microstent to treat mild-to-moderate, primary open-angle glaucoma in conjunction with cataract surgery. Roughly the size of ...
NEW ORLEANS -- Patients with glaucoma who were treated with a microstent during cataract surgery retained benefits over traditional surgery at 5 years, a randomized study found. In addition, rate of ...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the closing of its previously announced acquisition of ...
Please provide your email address to receive an email when new articles are posted on . Ivantis announced the FDA approval of the Hydrus microstent, designed to treat patients with mild to moderate ...
Alcon AG reported its plans to acquire Ivantis Inc., adding the Hydrus microstent for glaucoma to its ophthalmology portfolio. Ivantis will receive $475 million at closing, with additional unspecified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results